Oral Arsenic-Containing Qinghuang Powder:A Potential Drug for Myelodysplastic Syndromes

Jing MING; Wei-yi LIU; Hai-yan XIAO; Yong-gang XU; Rou MA; Xiao-mei HU

doi:10.1007/s11655-020-3254-9

Your Location：

Home >

Browse articles >

Oral Arsenic-Containing Qinghuang Powder:A Potential Drug for Myelodysplastic Syndromes

Review | Updated：2022-07-20

- Oral Arsenic-Containing Qinghuang Powder:A Potential Drug for Myelodysplastic Syndromes
- Chinese Journal of Integrative Medicine Vol. 28, Issue 8, Pages: 762-768(2022)
- Affiliations：
  
  Department of Hematology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing (100091), China
- Author bio：
  
  Prof. HU Xiao-mei, E-mail:huxiaomei_2@163.com
- Funds：
- DOI：10.1007/s11655-020-3254-9
  CLC：
- Published：2022-08，
  
  Published Online：07 March 2020，
  
  Accepted：17 December 2019
Scan for full text
Jing MING, Wei-yi LIU, Hai-yan XIAO, et al. Oral Arsenic-Containing Qinghuang Powder:A Potential Drug for Myelodysplastic Syndromes. [J]. Chinese Journal of Integrative Medicine 28(8):762-768(2022)
DOI：

Jing MING, Wei-yi LIU, Hai-yan XIAO, et al. Oral Arsenic-Containing Qinghuang Powder:A Potential Drug for Myelodysplastic Syndromes. [J]. Chinese Journal of Integrative Medicine 28(8):762-768(2022) DOI： 10.1007/s11655-020-3254-9.

摘要

青黄散 (QHP) 是一种口服砷剂

多年来已成为中国中医科学院西苑医院治疗骨髓增生异常综合征 (MDS) 的有效药物

QHP 的活性成分 As

已被阐明. 考虑到相对安全、免化疗和口服方便的特点

QHP已被广泛用于MDS患者的临床治疗

尤其是老年患者的治疗. 在这篇综述中

作者概述了口服含砷化合物 QHP 治疗 MDS 的疗效和安全性

特别关注 QHP 疗效与细胞遗传学、预后风险、DNA 甲基化、基因突变、血砷浓度、As

作用机制及胃肠道不良反应对策.

Abstract

Qinghuang Powder (QHP)

an oral arsenic

has become an effective drug in the treatment of myelodysplastic syndromes (MDS) in Xiyuan Hospital

China Academy of Chinese Medical Sciences for many years

and the action mechanism of the compound or active ingredient As

of QHP has been elucidated. Considering the relatively safety

chemotherapy-free and convenient oral profile

QHP is widely used in the clinical treatment for MDS patients

especially for elderly patients. In this review

the authors document the efficacy and safety of oral arsenic-containing compound QHP in the treatment of MDS

with a special focus on the association of efficacy of QHP with the cytogenetics

prognostic risk

DNA methylation

gene mutation

blood arsenic concentration

mechanism of action of As

and the countermeasures against adverse reactions of gastrointestinal tract.

关键词

Keywords

arsenicQinghuang Powdermyelodysplastic syndromesreviewChinese medicine

references

Ades L, Itzykson R, Fenaux P. Myelodysplastic syndromes.Lancet 2014;383:2239-2252.

Yu ZP, Ding JH, Sun AN, et al. A randomized study comparing stem cell transplantation versus conventional therapy for low- and intermediate-risk myelodysplastic Syndromes patients. Stem Cells Dev 2017;26:1132-1139.

Rollison DE, Howlader N, Smith MT, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001–2004, using data from the NAACCR and SEER programs. Blood 2008;112:45-52.

Schuler E, Zadrozny N, Blum S, et al. Long-term outcome of high risk patients with myelodysplastic syndromes or secondary acute myeloid leukemia receiving intensive chemotherapy. Ann Hematol 2018;97:2325-2332.

Lubbert M, Suciu S, Baila L, et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase Ⅲ study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol 2011;29:1987-1996.

List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006;355:1456-1465.

Raza A, Reeves JA, Feldman EJ, et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 2008;111:86-93.

van der Straaten HM, van Biezen A, Brand R, et al. Allogeneic stem cell transplantation for patients with acute myeloid leukemia or myelodysplastic syndrome who have chromosome 5 and/or 7 abnormalities. Haematologica 2005;90:1339-1345.

Hu XM, Ma R, Xu YG, et al. Treatment of hematologic malignancies with Qinghuang Powder. Int J Tradit Chin Med (Chin) 2011;33:568-570.

Hu XM, Liu F, Ma R. Application and assessment of Chinese arsenic drugs in treating malignant hematopathy in China. Chin J Integr Med 2010;16:368-377.

Zhou AX, Yao BS, Wang K, et al. Experience in the treatment of acute non-lymphocytic leukemia. Shanghai J Trad Chin Med (Chin) 1986;2:15-16.

Hosono N. Genetic abnormalities and pathophysiology of MDS. Int J Clin Oncol 2019;24:885-892.

Hu XM, Wang HZ, Mao C, et al. Clinical significance of trisomy 8 and monosomy 7/7q deletion in myelodysplastic syndrome. J Clin Hematol (Chin) 2006;19:340-343.

Hu XM, Xu YG, Quan RC, et al. Dysfunction of T lymphocytes and clone haematogenesis in patients with myelodysplastic syndrome. J Leuk Lymphoma (Chin) 2011;20:71-75.

Xu S, Ma R, Hu XM, et al. Clinical observation of the treatment of myelodysplastic syndrome mainly with Qinghuang Powder. Chin J Integr Med 2011;17:834-839.

Sun SZ, Ma R, Hu XM, et al. Karyotype and DNA-methylation responses in myelodysplastic syndromes following treatment with traditional Chinese formula containing arsenic. Evid-Based Compl Alt 2012;2012:969476.

Ma JL, Qu WW, Hu XM. Correlationship of clonal selection of treatment with arsenic-containing formula Qinghuang Powder in vivo effects of arsenic in patients with myelodysplastie syndrome. Chin J Inf Tradit Chin Med(Chin) 2013;20:8-10.

Zhou QB, Yang XH, Wang HZ, et al. Effect of Qinghuang Powder combined with Bupi Yishen Decoction in treating patients with refractory cytopenia with multilineage dysplasia through regulating DNA methylation. Chin J Integr Med 2019;25:354-359.

Deng ZY, Zhu SR, Wang MJ, et al. Relation of blood arsenic concentration with effect and safety of arsenic-containing Qinghuang Powder in patients with myelodysplastic syndrome. Chin J Integr Med 2019;25:497-501.

Chen B, Zhao WL, Jin J, et al. Clinical and cytogenetic features of 508 Chinese patients with myelodysplastic syndrome and comparison with those in Western countries.Leukemia 2005;19:767-775.

Wang H, Wang X, Xu X, et al. Cytogenetic features and prognosis analysis in Chinese patients with myelodysplastic syndrome: a multicenter study. Ann Hematol 2010;89:535-544.

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): "Myelodysplastic Syndromes (Version 1,2018)." Available at : http://www.nccn.orghttp://www.nccn.org. [2017-08-29].

Mozessohn L, Cheung MC, Fallahpour S, et al. Azacitidine in the 'real-world': an evaluation of 1101 higher-risk myelodysplastic syndrome/low blast count acute myeloid leukaemia patients in Ontario, Canada. Br J Haematol 2018;181:803-815.

Garcia-Manero G, Montalban-Bravo G, Berdeja JG, et al.Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher-risk myelodysplastic syndromes. Cancer 2017;123:994-1002.

Laribi K, Bolle D, Alani M, et al. Prognostic impact of elevated pretreatment serum ferritin in patients with high-risk MDS treated with azacitidine. Exp Hematol 2018;65:34-37.

Sohn SK, Moon JH, Lee IH, et al. No benefit of hypomethylating agents compared to supportive care for higher risk myelodysplastic syndrome. Korean J Intern Med 2018;33:1194-1202.

Zhu QZ, Xiao HY, Liu WY, et al. More benefits of oral administration of arsenic-containing Qinghuang Powder compared with decitabine for high/very-high risk myelodysplastic syndrome. World J Integr Tradit West Med(Chin) 2019;5:11-19.

Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002;100:2292-2302.

Cheson BD, Bennett JM, Kantarjian H, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000;96:3671-3674.

Zhu Q, Deng Z, Zhu S, et al. Study on the clinical safe and effective methods of arsenic-containing compound-Qinghuang Powder in the treatment of myelodysplastic syndrome. Evid Based Compl Alt 2017;2017:2095682.

Pellagatti A, Boultwood J. The molecular pathogenesis of the myelodysplastic syndromes. Eur J Haematol 2015;95:3-15.

Zhao P, Liang JB, Deng ZY, et al. Association of gene mutations with response to arsenic-containing Compound Qinghuang Powder in patients with myelodysplastic syndromes. Chin J Integr Med 2019;25:409-415.

Ma JL, Qu WW, Hu XM. The research development of the pharmacokinetics in treating hematological malignancy with the Chinese arsenic drugs. Int J Trad Chin Med 2012;34:80-82.

Lo-Coco F, Avvisati G, Vignetti M, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med 2013;369:111-121.

Qian LS, Zhao YZ. The cooperation group of phase Ⅱclinical trial of compound Huangdai tablet. phase Ⅱ clinical trial of compound Huangdai Tablet in newly diagnosed acute promyelocytic leukemia. Chin J Hematol (Chin)2006;27:801-804.

Burnett AK, Russell NH, Hills RK, et al. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised,controlled, phase 3 trial. Lancet Oncol 2015;16:1295-1305.

Sun F, Chen NN, Cheng YB. Compound Realgar and Natural indigo Tablets in treatment of acute promyelocytic leukemia: a summary of experience in 204 cases. J Chin Integr Med (Chin) 2008;6:639-642.

Wang DX, Ma R, Li L, et al. Retrostpective analysis on the effectiveness of Qinghuang Powder combined with Bushen Jianpi Formula and androgens for patients with myelodysplastic syndrome of refractory anemia with excess of blasts. Chin J Integr Tradit West Med (Chin) 2019;39:33-37.

Jiang Y, Dunbar A, Gondek LP, et al. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood 2009;113:1315-1325.

Hu XM, Tanaka S, Onda K, et al. Arsenic disulfide induced apoptosis and concurrently promoted erythroid differentiation in cytokine-dependent myelodysplastic syndrome-progressed leukemia cell line F-36p with complex karyotype including monosomy 7. Chin J Integr Med 2014;20:387-393.

Hu XM, Yuan B, Tanaka S, et al. Arsenic disulfide-triggered apoptosis and erythroid differentiation in myelodysplastic syndrome and acute myeloid leukemia cell lines.Hematology 2014;19:352-360.

Wu L, Li X, Chang C, Ying S, et al. Deviation of typeⅠ and type Ⅱ T cells and its negative effect on hematopoiesis in myelodysplastic syndrome. Int J Lab Hematol 2008;30:390-399.

Kochenderfer JN, Kobayashi S, Wieder ED, et al.Loss of T-lymphocyte clonal dominance in patients with myelodysplastic syndrome responsive to immunosuppression. Blood 2002;100:3639-3645.

Song MM, Fang S, Tanaka S, et al. Effects of arsenic disulfide on proliferation, cytokine production, and frequencies of CD4(+), CD8(+), and regulatory T cells in mitogen-activated human peripheral blood mononuclear cells. Int Immunopharmacol 2015;29:832-838.

Zhu HH, Wu DP, Du X, et al. Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority,randomised phase 3 trial. Lancet Oncol 2018;19:871-879.

Zhu HH, Hu J, Lo-Coco F, et al. The simpler, the better:oral arsenic for acute promyelocytic leukemia. Blood 2019;134:597-605.

More>

Views

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

Arsenic-Containing Qinghuang Powder (青黄散) Is An Alternative Treatment for Elderly Acute Myeloid Leukemia Patients Refusing Low-Intensity Chemotherapy

Relation of Blood Arsenic Concentration with Effect and Safety of Arsenic-Containing Qinghuang Powder (青黄散) in Patients with Myelodysplastic Syndrome

Effect of Qinghuang Powder (青黄散) Combined with Bupi Yishen Decoction (补脾益肾方) in Treating Patients with Refractory Cytopenia with Multilineage Dysplasia through Regulating DNA Methylation

Comparing Arsenic-Containing Qinghuang Powder and Low-Intensity Chemotherapy in Elderly Patients with Acute Myeloid Leukemia

Progress on Regulation of NLRP3 Inflammasome by Chinese Medicine in Treatment of Ulcerative Colitis

Related Author

No data

Related Institution

Graduate School, China Academy of Chinese Medical Sciences

Graduate School of China Academy of Chinese Medical Sciences

Graduate School of Beijing University of Chinese Medicine

Zhengyuan Clinic of Nantong

National Hematological Medical Center of Traditional Chinese Medicine, Department of Hematology, Xiyuan Hospital, China Academy of Chinese Medical Sciences

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰